STOCK TITAN

Larimar Therapeutics Inc - LRMR STOCK NEWS

Welcome to our dedicated news page for Larimar Therapeutics (Ticker: LRMR), a resource for investors and traders seeking the latest updates and insights on Larimar Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Larimar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Larimar Therapeutics's position in the market.

Rhea-AI Summary
Larimar Therapeutics to participate in panel discussion and investor meetings at Citi BioPharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
-
Rhea-AI Summary
Larimar Therapeutics has received FDA clearance to initiate the 50 mg cohort in the Phase 2 trial for Friedreich's ataxia (FA) and the open-label extension (OLE) trial. Top-line data from the 50 mg cohort is expected in 1H 2024. Cash, cash equivalents, and marketable securities as of June 30, 2023, were $104.2 million. Larimar reported a net loss of $8.4 million for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
-
Rhea-AI Summary
LRMR - Larimar Therapeutics, Inc. appoints Dr. Russell Clayton as Chief Medical Officer, succeeding Dr. Nancy Ruiz. Dr. Clayton brings extensive experience in rare disease treatments and clinical trial design. The company also granted Dr. Clayton an inducement award of 180,000 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
management
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.99%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
Larimar Therapeutics Inc

Nasdaq:LRMR

LRMR Rankings

LRMR Stock Data

444.05M
32.55M
1.34%
83.55%
5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bala Cynwyd

About LRMR

larimar therapeutics, inc. (nasdaq:lrmr), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. the company’s lead compound, cti-1601, is currently being evaluated in a phase 1 clinical program as a potential treatment for friedreich’s ataxia, a rare and progressive genetic disease. larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. for more information, please visit: https://larimartx.com.